Tirzepatide

Tirzepatide is a synthetic 39 amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid chain enabling albumin binding and a plasma half-life of approximately 5 days. Structurally based on the native GIP sequence with modifications for GLP-1R co-agonism, it demonstrates full agonism at GIPR and partial, beta-arrestin-biased agonism at GLP-1R — a pharmacological distinction from balanced GLP-1R agonists such as Semaglutide that is studied in receptor internalisation and desensitisation research. Molecular formula: C225H348N48O68 | Molecular weight: 4813.46 g/mol | CAS: 2023788-19-2 | Drug class: Dual GIP/GLP-1R agonist | Purity: greater than or equal to 98% as verified by HPLC | Form: Lyophilised powder | Appearance: White to off-white lyophilised powder | Storage: -20°C desiccated GIPR is expressed on pancreatic beta cells, adipose tissue, bone, and — critically for appetite research — hypothalamic neurons. Research using Tirzepatide has examined whether central GIPR activation synergises with central GLP-1R signalling for energy balance regulation, and whether GIPR co-agonism produces qualitatively different metabolic effects from GLP-1R agonism alone. Coskun et al. (JCI Insight, 2020) characterised Tirzepatide's imbalanced receptor pharmacology and biased GLP-1R agonism in detail. Research applications include comparative receptor pharmacology assays (Tirzepatide versus Semaglutide versus Retatrutide), GIPR and GLP-1R functional studies, biased agonism investigations at GLP-1R, and metabolic signalling research in beta cell, adipocyte, and hypothalamic cell models. Supplied as a lyophilised powder. Reconstitute with bacteriostatic water. Store at -20°C protected from light and moisture. For laboratory and analytical research purposes only. Not for human or veterinary use.